Design of peptides interfering with iron-dependent regulator (IdeR) and evaluation of Mycobacterium tuberculosis...

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Microbiology

Background:

• Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a global health threat with high mortality.
• Long-term TB treatment increases the risk of drug resistance, necessitating novel therapeutic strategies.
• Targeting essential bacterial proteins like the iron-dependent regulator (IdeR) presents a promising approach for new drug development.

Purpose of the Study:

• To design and identify novel peptide inhibitors targeting the iron-dependent regulator (IdeR) of Mycobacterium tuberculosis.
• To evaluate the in vitro efficacy and mechanism of action of designed peptide inhibitors against Mtb.
• To explore potential new anti-tubercular therapies through IdeR inhibition.

Main Methods:

• In silico modeling and molecular docking were used to design 50 short peptides targeting IdeR.
• Top 10 peptide candidates underwent in vitro validation, including DNA binding assays, microplate alamar blue assays, and colony counting.
• Quantitative real-time PCR (qRT-PCR) and iron estimation assays were performed to elucidate the mechanism of action.

Main Results:

• Two synthesized peptides, glycine-valine-proline-glycine (GVPG) and arginine-proline-arginine (RPR), demonstrated in vitro inhibition of Mtb at 200 μM.
• qRT-PCR revealed significant overexpression of the mbtB gene (58-fold), correlating with Mtb growth inhibition.
• Cell wall-associated mycobactin and whole-cell iron estimations corroborated the qRT-PCR findings, confirming IdeR pathway disruption.

Conclusions:

• GVPG and RPR represent promising lead compounds for developing novel anti-tubercular drugs.
• The study validates IdeR as a viable drug target for combating Mycobacterium tuberculosis.
• These findings contribute to the ongoing search for more potent and effective therapies against tuberculosis.